CDKN1A and glioblastoma: These findings suggest that GBM patients with the AA (Arg/Arg) and CA (Ser/Arg) genotypes of CDKN1A c.93C > A have significantly longer overall survival intervals when treated with CCRT plus bevacizumab compared to those with the CC (Ser/Ser) genotype in the same treatment group.